Research Topics
| J H SchillerSummaryAffiliation: University of Wisconsin Country: USA Publications
| Collaborators
|
Detail Information
Publications
Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in EuropeJoan Schiller
University of Wisconsin Hospital, Room K4 538, 600 Highland Avenue, Madison, WI 53792, USA
Lung Cancer 43:101-12. 2004....- Adjuvant systemic therapies in early-stage non-small-cell lung cancerJoan H Schiller
Medical Oncology, University of Wisconsin Hospital and Clinics, Madison, USA
Clin Lung Cancer 5:S29-35. 2003..A combination of these new approaches and standard therapy for NSCLC may improve long-term survival in patients with lung cancer.. - Small cell lung cancer: defining a role for emerging platinum drugsJoan H Schiller
University of Wisconsin Hospital, Madison, 53792, USA
Oncology 63:105-14. 2002..If the early promise shown by these compounds is confirmed in the clinic, they may offer a new approach to the treatment of SCLC, including recurrent disease for which limited treatment options are currently available... - Study design issues and early stage non-small cell lung cancerJoan H Schiller
University of Wisconsin Comprehensive Cancer Center, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
Clin Cancer Res 11:5030s-5032s. 2005..Education of health care professionals regarding the benefits of adjuvant therapies, to decrease a sense of nihilism and to increase referrals, and international collaborations may also be necessary to increase accrual... - Current standards of care in small-cell and non-small-cell lung cancerJ H Schiller
University of Wisconsin Hospital and Clinics, Madison, 53792, USA
Oncology 61:3-13. 2001..This article reviews the current standards of care in SCLC and NSCLC, and introduces the potential role of newer agents given in combination with standard chemotherapy... - Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology GroupJ H Schiller
University of Wisconsin Hospital and Clinics, Madison, WI 53792, USA
J Clin Oncol 19:2114-22. 2001..To determine the efficacy of topotecan in combination with standard chemotherapy in previously untreated patients with extensive-stage small-cell lung cancer (SCLC), the Eastern Cooperative Oncology Group (ECOG) conducted a phase III trial... - Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant TherapyJ H Schiller
William S Middleton Veterans Administration Hospital and University of Wisconsin, Madison 53792, USA
J Clin Oncol 19:448-57. 2001..To determine the prognostic and predictive significance of p53 and K-ras mutations in patients with completely resected non-small-cell lung cancer (NSCLC)... - Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularizationJ H Schiller
William S Middleton Veterans Administration Hospital and University of Wisconsin Department of Medicine, Madison 53705, USA
Clin Cancer Res 5:4287-94. 1999..These data demonstrate that the combination of squalamine and a platinum analog has significant preclinical antitumor activity against human lung cancer that is related to the anti-angiogenic effects of squalamine... - Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survivalJ H Schiller
Department of Human Oncology, University of Wisconsin, Madison, USA
J Clin Oncol 14:1913-21. 1996.... - Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group TrialJ H Schiller
University of Wisconsin Comprehensive Cancer Center, Madison 53792, USA
J Clin Oncol 14:2345-52. 1996.... - Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapyK M Leu
Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
Lung Cancer 34:105-13. 2001.... - Future role of topotecan in the treatment of lung cancerJ H Schiller
University of Wisconsin Hospital, Madison, 53792, USA
Oncology 61:55-9. 2001..Preliminary results of some of these trials are presented in this summary. The results of other clinical experience trials are eagerly anticipated... - Loss of the tumorigenic phenotype with in vitro, but not in vivo, passaging of a novel series of human bronchial epithelial cell lines: possible role of an alpha 5/beta 1-integrin-fibronectin interactionJ H Schiller
William S Middleton Veterans Administration Hospital, Madison, Wisconsin 53705, USA
Cancer Res 55:6215-21. 1995.... - Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcomaD M Mahvi
Department of Surgery, H4 726 Clinical Science Center, Madison, Wisconsin 53792, USA
Hum Gene Ther 8:875-91. 1997..Restaging of the patients' disease and long term toxicity evaluation will be performed at 3, 6, and 12 months and then yearly... - Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2M E Eastman
Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
Cancer 91:806-14. 2001..The risk of DRT appears to be higher than the risk reported for patients with similar devices but not given IL-2. Low dose warfarin did not prevent DRT when started after device placement... - Phase I study of docetaxel and topotecan in patients with advanced malignanciesSarita Dubey
Department of Medicine, Medical Oncology Section, University of Wisconsin Comprehensive Cancer Center, Madison, USA
J Oncol Pharm Pract 11:131-8. 2005..We designed a phase I study to evaluate the maximum tolerated dose of this combination and to assess the impact of pharmacokinetic interactions of the two drugs on toxicity... - Early stage lung cancer--new approaches to evaluation and treatment: conference summary statementThomas J Lynch
Division of Hematology/Oncology and Dana-Farber/Partners Cancer Care, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
Clin Cancer Res 11:4981s-4983s. 2005 - Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancerTien Hoang
Ohio State University College of Medicine and Comprehensive Cancer Center, Columbus, Ohio, USA
J Thorac Oncol 1:218-25. 2006..1 months in phase II), we did not observe a clear survival advantage and thus do not plan to further investigate this schedule of gemcitabine and exisulind... - Angiogenesis inhibitors in the treatment of lung cancerSophie Sun
Division of Hematology and Oncology, University of Texas Southwestern, Dallas 75390 8852, USA
Crit Rev Oncol Hematol 62:93-104. 2007..Recent clinical trials have yielded promising results. This article will review angiogenesis inhibitors targeting the VEGF pathway which are currently being developed for the treatment of lung cancer... 
Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590Daniel B Costa
Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, MA, United States
Lung Cancer 56:97-103. 2007..This is the first comprehensive study of this transcription factor in patients with NSCLC...- Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerAlan Sandler
Vanderbilt University, Nashville, TN, USA
N Engl J Med 355:2542-50. 2006..Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers... - Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancerMichael P Fanucchi
Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
J Clin Oncol 24:5025-33. 2006..Additional investigation of bortezomib in NSCLC is warranted in combination with other drugs known to be active, or using different schedules... - Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup TrialHeather A Wakelee
Stanford Cancer Center, CA 94305 5826, USA
Clin Lung Cancer 8:18-21. 2006..Because of the recent update, this trial will now limit patients with stage IB disease to those with larger tumors (>or= 4 cm) and will likely include only cisplatin-based regimens... - PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2Kathy S Albain
Loyola University, Chicago Medical Center, Maywood, IL 60153, USA
Clin Lung Cancer 7:417-9. 2006 - Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990Heather A Wakelee
Department of Medicine, Division of Medical Oncology, Stanford Cancer Center, Stanford University, Stanford, California 94305 5826, USA
Cancer 106:2208-17. 2006.... - Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594Heather A Wakelee
Department of Medicine, Division of Oncology, Stanford University, Stanford, CA 94305 5826, USA
J Thorac Oncol 1:441-6. 2006..E1594 randomized patients with advanced NSCLC to one of four platinum doublets and found that all four regimens had comparable efficacy... 
Assessment of guilt and shame in patients with non-small-cell lung cancer compared with patients with breast and prostate cancerNoelle K Loconte
University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, WI 53792, USA
Clin Lung Cancer 9:171-8. 2008..This study was designed to determine the levels of guilt and shame among patients with non-small-cell lung cancer (NSCLC) compared with breast and prostate cancer...- Noninvasive monitoring of tumorsJoan H Schiller
N Engl J Med 359:418-20. 2008 - Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab--an Eastern Cooperative Oncology Group StudyAfshin Dowlati
University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, Ohio 44016, USA
Clin Cancer Res 14:1407-12. 2008.... - Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599Suresh S Ramalingam
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA
J Clin Oncol 26:60-5. 2008..We conducted a subset analysis of ECOG 4599 to determine the outcome for elderly patients... - A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)Kishan J Pandya
James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
J Thorac Oncol 2:1036-41. 2007..To study the progression-free survival (PFS) and toxicity with 25- or 250-mg doses of temsirolimus (CCI-779) after induction chemotherapy in patients with extensive small-cell lung cancer... - Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancerRoy S Herbst
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Clin Cancer Res 13:6175-81. 2007..Based on supporting preclinical studies, we undertook a Phase II trial of pertuzumab in patients with recurrent non-small cell lung cancer (NSCLC)... - Addressing the current challenges of non-small-cell lung cancer clinical trial accrualWalter J Curran
Department of Radiation Oncology, The Emory Clinic, Atlanta, GA 30322, USA
Clin Lung Cancer 9:222-6. 2008.... - Lung cancer in never smokers--a different diseaseSophie Sun
Division of Haematology and Oncology and Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Nat Rev Cancer 7:778-90. 2007..This Review summarizes our current knowledge of this unique and poorly understood disease... - Differences in primary care clinicians' approach to non-small cell lung cancer patients compared with breast cancerTimothy R Wassenaar
University of Wisconsin School of Medicine and Public Health, Department of Medicine, Madison, Wisconsin, USA
J Thorac Oncol 2:722-8. 2007..We conducted a survey of primary care physicians to determine whether treatment and referral patterns of breast cancer patients differed from those of lung cancer patients... - Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysisAndrea Ardizzoni
Division of Medical Oncology, University Hospital, Via Gramsci 14, 43100 Parma, Italy
J Natl Cancer Inst 99:847-57. 2007..Because the efficacy of carboplatin and cisplatin in the treatment of advanced non-small-cell lung cancer (NSCLC) has not been proven to be equivalent, an individual patient data meta-analysis comparing the two treatments was performed... - Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximabSarita Dubey
University of Wisconsin Comprehensive Cancer Center, 600 Highland Avenue, Madison, Wisconsin 53792, USA
Oncologist 10:282-91. 2005..All three drugs are approved for different tumor types, and studies defining their role in NSCLC are under way... - Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1Giuseppe Giaccone
Vrije Universiteit Medical Center, Department of Oncology, De Boelelaan 1117, 1081 Amsterdam, The Netherlands
J Clin Oncol 22:777-84. 2004..Gefitinib has demonstrated encouraging efficacy in advanced NSCLC in phase II trials in pretreated patients, and a phase I trial of gefitinib in combination with gemcitabine and cisplatin showed favorable tolerability... - Chemotherapy for advanced non-small cell lung cancerSarita Dubey
Department of Medicine, University of Wisconsin, University of Wisconsin Comprehensive Cancer Center, 600 Highland Avenue, Madison, WI 53792, USA
Hematol Oncol Clin North Am 18:101-14. 2004..In second-line setting, docetaxel is the agent that has been extensively studied and approved. Furthermore, molecularly targeted therapy holds a promising future and is discussed in articles elsewhere in this issue... - Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2Roy S Herbst
Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
J Clin Oncol 22:785-94. 2004..This phase III, randomized, placebo-controlled, double-blind trial evaluated gefitinib plus paclitaxel and carboplatin in chemotherapy-naive patients with advanced NSCLC... - New directions for ZD1839 in the treatment of solid tumorsJoan H Schiller
Section of Medical Oncology, Department of Medicine, University of Wisconsin Medical School, Comprehensive Cancer Center, Madison, WI 53792-6164, USA
Semin Oncol 30:49-55. 2003..Chemoprevention trials have been initiated to assess the potential of ZD1839 to delay or prevent the progression of common solid tumors such as non-small cell lung cancer... - Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trialMark G Kris
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center and the Weill Medical College of Cornell University, New York, NY 10021, USA
JAMA 290:2149-58. 2003..04) and diarrhea (P =.006). CONCLUSIONS: Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy... - A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancerRoy S Herbst
Department of Thoracic/Head and Neck Medical Oncology and Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
Clin Cancer Res 9:4108-15. 2003.... - Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancerTien Hoang
Room K4/538, Clinical Science Center, University of Wisconsin, 600 Highland Avenue, Madison, WI 53792, USA
Lung Cancer 42:97-102. 2003..Respiratory failure and death, possibly related to pulmonary toxicity, was observed in one patient (3.7%). CONCLUSION: monotherapy gemcitabine as second-line agent has limited activity in previously treated SCLC... - Platin or no platin? That is the questionJoan H Schiller
J Clin Oncol 21:3009-10. 2003 - Novel therapies for the treatment of non-small cell lung cancerDavid H Johnson
Division of Hematology and Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, 777 Preston Research Building, Nashville, TN 37232 6307, USA
Cancer Chemother Biol Response Modif 20:763-86. 2002..In addition, we need new techniques to assist those who are already addicted to escape from tobacco's death grip. Sadly, most users of tobacco still fail to recognize the dangers of their habit. This needs to change!.. - Novel agents in the treatment of lung cancer: conference summary statementThomas J Lynch
Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
Clin Cancer Res 10:4199s-4204s. 2004 - Clinical trial design issues in the era of targeted therapiesJoan H Schiller
University of Wisconsin Madison, Wisconsin, USA
Clin Cancer Res 10:4281s-4282s. 2004..Although our lack of effective therapies mandates the development of new, molecularly targeted therapies, a number of issues in the design of clinical trials and their end points remain to be considered... - Comparison of four chemotherapy regimens for advanced non-small-cell lung cancerJoan H Schiller
University of Wisconsin Hospital and Clinics, Madison, USA
N Engl J Med 346:92-8. 2002..CONCLUSIONS: None of four chemotherapy regimens offered a significant advantage over the others in the treatment of advanced non-small-cell lung cancer... - Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trialDavid Cella
Evanston Northwestern Healthcare and Northwestern University, 1001 University Place, Ste 100, Evanston, IL 60201, USA
J Clin Oncol 23:2946-54. 2005..Among these NSCLC patients treated with gefitinib, symptom improvement was complementary to and, for most patients, preceded evidence of radiographic regression... - Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group dataTien Hoang
University of Wisconsin Medical School, 600 Highland Ave, K4 562, Madison, WI, USA
J Clin Oncol 23:175-83. 2005.... - Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumorsDiane R Mould
Projections Research Inc, 535 Springview Lane, Phoenixville, PA 19460, USA
Clin Pharmacol Ther 71:334-48. 2002..The use of covariates to individualize dose would result in less variability in exposure, reducing the likelihood of severe neutropenia and potentially improving treatment benefit... - Systemic treatment of advanced non-small cell lung cancerAnne M Traynor
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin 53792, USA
Drugs Today (Barc) 40:697-710. 2004.... - Novel therapies for lung cancerTien Hoang
Department of Medicine, Medical Oncology, University of Wisconsin Medical School, Madison, WI 53792, USA
Surg Oncol 11:229-41. 2002.... - Can current treatments for advanced non-small-cell lung cancer be improved?Athanassios Argiris
JAMA 292:499-500. 2004 - Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 diseaseSteven M Keller
Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY 10467, USA
J Thorac Cardiovasc Surg 128:130-7. 2004.... - Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapyTien Hoang
Department of Medicine, University of Wisconsin Medical School, Madison 53792, USA
Expert Rev Anticancer Ther 2:393-401. 2002..These novel agents target molecular pathways specifically found in cancer cells, thus maximizing the antitumor effect while minimizing toxicities on normal cells... - Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumorsJames P Thomas
Department of Medicine, Section of Medical Oncology and University of Wisconsin Comprehensive Cancer Center, University of Wisconsin Medical School, Madison, 53792, USA
J Clin Oncol 21:223-31. 2003..CONCLUSION: Endostatin given daily as a 1-hour intravenous infusion was well tolerated without dose-limiting toxicity at doses up to 300 mg/m2... - Developments in epidermal growth factor receptor-targeting therapy for solid tumors: focus on matuzumab (EMD 72000)Joan H Schiller
University of Texas Southwestern, Dallas, Texas 75390 8852, USA
Cancer Invest 26:81-95. 2008..Skin rash is the most common toxicity, but is severe (Grade 3) in < 1 percent. This article describes preclinical and clinical development of matuzumab... - EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancerSarita Dubey
University of California, San Francisco, San Francisco, California 94115, USA
J Thorac Oncol 1:406-12. 2006..The authors hypothesized that a shorter length of tumor SSR would be associated with poorer survival in patients with non-small cell lung cancer (NSCLC)... - Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancerSarita Dubey
University of Wisconsin Comprehensive Cancer Center, Madison 53792, USA
J Support Oncol 3:149-54. 2005..Better communication between physician and patient about the likelihood of side effects may reduce chemotherapy-related stress for patients... - Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungsGregory A Otterson
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
Clin Cancer Res 13:1246-52. 2007..To evaluate the toxicity profile of inhalational doxorubicin in patients with malignant disease in the lung... - Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patientsDavid M King
University of Wisconsin, Madison, WI 53792, USA
J Clin Oncol 22:4463-73. 2004..CONCLUSION: Treatment with the immunocytokine EMD 273063 induced immune activation and was associated with reversible clinical toxicities at the MTD of 7.5 mg/m2/d in melanoma patients... - Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancerHeather A Wakelee
Oncology Division, Stanford University School of Medicine, CA, USA
Clin Lung Cancer 7:S31-8. 2005..We present phase I data (and phase II/III data when available) of these compounds and discuss their potential development in the treatment of lung cancer... - Using liquid crystals to report membrane proteins captured by affinity microcontact printing from cell lysates and membrane extractsChang-Hyun Jang
Department of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA
J Am Chem Soc 127:8912-3. 2005..Detection of epidermal growth factor receptor, a transmembrane glycoprotein, is demonstrated... - New molecularly targeted therapies for lung cancerSophie Sun
Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
J Clin Invest 117:2740-50. 2007..This article will review the important clinical implications of these advances, with a focus on new molecularly targeted therapies currently in development...